ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing in emerging medical technology and biopharmaceutical companies, today announced the promotion of Niall O’Donnell, Ph.D., to principal. Read More…
ST. LOUIS, MO – RiverVest Venture Partners announced today that it has completed fundraising for its second fund, RiverVest Venture Fund II, L.P., with total committed capital of $75 million from private investors. RiverVest’s first fund, which was licensed as a Small Business Investment Company, had total private capital of $45 million,plus one tier of leverage from the Small Business Administration.
ST. LOUIS, MO and CLEVELAND, OH - RiverVest Venture Partners, a life science venture capital firm headquartered in St. Louis, MO, announced today that it will be opening an office at the BioEnterprise facility in Cleveland, OH. The office will be managed by Karen Spilizewski, who is joining RiverVest on a part-time basis as a vice president on January 1, 2008. RiverVest co-founder and managing director, Jay Schmelter, said, “We are excited about the investment prospects in Ohio, which led all Midwestern states in life science venture capital investments through the first nine months of 2007.
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, today announced that Gordon Foulkes, Ph.D., has joined the firm as a Venture Partner. Dr. Foulkes brings to RiverVest extensive operational experience in biopharmaceutical research and development. Prior to joining RiverVest, he headed research and development in three biotechnology companies where he helped raise $145 million in private and public offerings and secure more than $200 million in 15 corporate partnerships.
